Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Inovio Pharmaceuticals

These two companies have been left in the dust. Is it too late for them?

2 Contenders in the Coronavirus Vaccine Market -- Are They Buys?

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2022 in Washington, D.C. on Wednesday, April 20, 2022 at 3:55 p.m. ET.

Vaxart to Present at World Vaccine Congress Washington 2022 on April 20

Moderna

Vertex Pharmaceuticals

Their products could deliver major revenue over time.

3 Biotech Stocks That Could Help Make You a Fortune

Geron

Rivian Automotive

These stocks are expected to grow their sales by 26,519% to 100,236% over the next five years.

3 of the Fastest-Growing Stocks on the Planet Through 2026

Novavax

Ocugen, Inc.

Select analysts foresee these coronavirus stocks rocketing higher by 246% to 355% over the next year.

3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall Street

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Vaxart, Inc. (NASDAQ: VXRT) on behalf of long-term stockholders following a class action complaint that was filed against Vaxart on August 24, 2020 with a Class Period from June 25, 2020 to July 25, 2020. Our investigation concerns whether the board of directors of Vaxart have breached their fiduciary duties to the company. The complaint alle

VAXART ALERT: Bragar Eagel & Squire, P.C. is Investigating Vaxart, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Is Vaxart the Next Moderna?

Bionano Genomics

Ginkgo Bioworks Holdings

These stocks are all about cutting-edge technology.

3 No-Brainer Stocks to Buy Right Now for Less Than $6

The past 12 months have been difficult for the biotech stock.

Is It Too Late to Buy Vaxart Stock?

These 19 Words From Vaxart Could Mean Trouble for Vaccine Rivals

Results from the phase 2 study using the oral vaccine Covid-19 treatment is expected in the 1st half of 2022.

Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

VAXART, INC. (VXRT) delivered earnings and revenue surprises of 0% and 69.55%, respectively, for the quarter ended December 2021.

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates

Company begins 2022 with multiple active programs with data readouts expected this year

Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19

Vaxart's S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

VAXART, INC. (VXRT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: VAXART, INC. (VXRT) Q4 Earnings Expected to Decline

Pharmaceutical Industry Veteran Brings Broad Legal Expertise  to Vaxart Senior Management Team

Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

This vaccine company has a lot of catching up to do.

Is Vaxart Stock a Buy Now?

VAXART, INC. (VXRT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About VAXART, INC. (VXRT) Rating Upgrade to Buy

Does Vaxart's Oral COVID Vaccine Have a Chance?

Intercept Pharma

Select analysts and investment banks believe these little-known companies can skyrocket.

4 Under-the-Radar Stocks With 319% to 645% Upside in 2022, According to Wall Street

Could Vaxart's Vaccine Pill Help to End the Pandemic?

Marathon Digital Holdings

Nikola

This diverse mix of companies is expected to deliver revenue growth of 236% to 5,460% this year.

4 of the Fastest-Growing Stocks on the Planet in 2022

This biotechnology company has a nifty trick up its sleeve.

Is This Vaccine Stock a Buy?

VXRT stock is more than a Covid-19 meme trade. But is there enough fundamentals there to support an investment heading into 2022?

Vaxart: Oral Covid-19 Vaccine Is Interesting, But Questions Linger

As the Covid-19 vaccine maker expands into a second manufacturing facility, VXRT stock remains an undervalued gem. The post Vaxart Deserves More Respect on Wall Street for Its Promising Covid-19 Vaccine appeared first on InvestorPlace.

News for Vaxart Stock (VXRT)